Orogen Royalties Inc.’s (CVE:OGN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Simply Wall St

Fri, Jul 18, 2025, 6:09 AM 3 min read

It is hard to get excited after looking at Orogen Royalties’ (CVE:OGN) recent performance, when its stock has declined 19% over the past week. However, the company’s fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements. Specifically, we decided to study Orogen Royalties’ ROE in this article.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

So, based on the above formula, the ROE for Orogen Royalties is:

5.0% = CA$3.5m ÷ CA$70m (Based on the trailing twelve months to March 2025).

The ‘return’ is the amount earned after tax over the last twelve months. Another way to think of that is that for every CA$1 worth of equity, the company was able to earn CA$0.05 in profit.

Check out our latest analysis for Orogen Royalties

We have already established that ROE serves as an efficient profit-generating gauge for a company’s future earnings. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don’t have the same features.

At first glance, Orogen Royalties’ ROE doesn’t look very promising. Next, when compared to the average industry ROE of 10.0%, the company’s ROE leaves us feeling even less enthusiastic. Despite this, surprisingly, Orogen Royalties saw an exceptional 41% net income growth over the past five years. So, there might be other aspects that are positively influencing the company’s earnings growth. Such as – high earnings retention or an efficient management in place.

We then compared Orogen Royalties’ net income growth with the industry and we’re pleased to see that the company’s growth figure is higher when compared with the industry which has a growth rate of 19% in the same 5-year period.